Orphan Drug Loophole Shields Blockbuster Drugs From Price Negotiations.

The article discusses the implications of the One Big Beautiful Bill Act, which exempts orphan drugs from Medicare price negotiations, particularly affecting high-revenue oncology drugs. This legislation may incentivize manufacturers to prioritize the development of treatments for rare diseases, potentially delaying the availability of affordable medications for more common conditions. Analyses indicate that nearly one-third of high-spending drugs will be exempt or delayed from negotiations, which could undermine the goals of the Inflation Reduction Act and lead to increased insurance premiums and out-of-pocket costs for Medicare beneficiaries. The article highlights specific drugs, such as Keytruda and Opdivo, that will benefit from these exemptions, raising concerns about the financial burden on taxpayers and patients. [Extracted from the article]